

## Supplementary Material:

### Expanded Methods:

#### Sequencing Quality Control

Small RNA was aligned using miRExpress and MINTmap. Total reads (after flexbar with quality control): 500,488,798. Reads per sample: 10,214,057 +/- (SD) 4,605,190. No significant difference between groups. Total miRNA: 284,749,858. miRNA hit / (hit+nohit): 56% +/- (SD) 4.4%. Total tRF (exclusive to tRNA space, see MINTmap documentation): 1,637,476. tRF (exclusive to tRNA space, see MINTmap documentation) hit / total reads: 3238 ppm +/- (SD) 1421 ppm. FastQC: All analyzed samples/bases showed exceptional quality. These metrics and FastQC results can be viewed at <https://github.com/slobentanzer/stroke-trf>.

At present, no standardized method exists to directly compare absolute counts derived from two separate alignments of the same sequencing experiment, as is the case here with the miRExpress and MINTmap alignments; MINTmap is a much more stringent pipeline (at least for the “exclusive tRNA space” used here). Future experiments should include a spike-in procedure or a similar approach to estimate absolute transcript numbers for each smRNA species, and to enable a better comparison between those absolute values.

Large RNA: Total reads (after flexbar with quality control): 880,069,396. Reads per sample: 36,669,558 +/- (SD) 4,543,364. No significant difference between groups. Mean mapping rate 89% +/- (SD) 2%. FastQC: All analyzed samples/bases showed exceptional quality. These metrics and FastQC results can be viewed at <https://github.com/slobentanzer/stroke-trf>.

#### Differential expression analysis

Differential expression was determined using the R/DESeq2 package (1) including the log2 fold change shrinkage estimation “apeglm” algorithm (2). Genes were considered differentially expressed at an adjusted p-value of < 0.05. The analysis was performed on the raw count tables (outliers already removed) with correction of covariates (age, batch, time2blood) in the model formula. Outliers were identified by sample clustering based on batch-corrected variance-stabilized expression, leading to exclusion of sample 4044 (stroke patient) in the small RNA sequencing experiment.

#### The count-change metric

The log-fold change metric is not ideally suited for assessing the potential impact of expression changes for individual small RNAs, because it does not reflect mean expression levels. We calculated the count-change for individual miRs and tRFs by combining base mean expression with the de-logarithmicized fold-change (from DESeq2 output).

$$CC = (BM \times 2^{LFC}) - BM$$

CC: countChange, BM: baseMean, LFC: log2-fold change

#### Small RNA targeting predictions

miR targeting was analyzed via our in-house database, *miRNeo*, as described (3). Briefly, the database unites 10 prediction algorithms and all available experimentally validated miR:gene interactions, and unites them in a scoring system. For all analyses in this manuscript, the cutoff score for consideration of a valid miR:gene interaction was  $\geq 6$ .

Since no comprehensive tRF targeting predictions are available, we performed our own prediction based on all tRFs detected with more than 10 reads on average. We used the TargetScan 7.0 algorithm (4) to determine putative miR-like binding of any 7-nucleotide substring (“seed”) of any tRF to any human transcript 3'-UTR. Hits were scored according to conserved branch length (BL) and probability of conserved targeting (PCT) across all 23 available species (5) and were entered into *miRNeo* (seed-gene targeting and tRF-seed association).

#### Gene set compilation of cholinergic and associated genes

We started out with a set of 28 cholinergic genes described in (6), targets including ACLY, CHAT, VACHT (aka SLC18A3), the 16 nicotinic and 5 muscarinic receptor subtypes, ACHE, BCHE, PRIMA1, and CHT (aka SLC5A7). In addition, we added several groups of genes known to be associated with

cholinergic functioning and of interest to our aims. These include: genes from the neurokinin and neurotrophin signaling pathways; families of genes implicated in the development and differentiation of cholinergic cell types, including lim-homeobox transcription factors, bone morphogenetic protein family genes, and genes from the JAK-STAT pathway (see [Data File S2](#))

miRs were considered Cholino-miRs if they were validated or predicted (with a score  $> 5/10$ ) to target at least 5 transcripts on this list; tRFs were considered Cholino-tRFs if they contained a seed targeting evolutionarily conserved binding sites in at least 5 transcripts on this list ([Figure S2](#) for empirical cumulative distribution function, ECDF plot); because of diverging numbers between miRs and tRFs we chose to use the higher (more stringent) threshold for miRs. Transcription factors were similarly associated with each transcript on the list, using the transcription factor activity derived from (7) in circulatory immune cells.

### Permutation targeting analysis

Where appropriate, we determined permutation p-values via *miRNeo* targeting permutation. We determined a score for the test condition (e.g. by summing the individual targeting scores of all DE miRs towards cholinergic genes) and compared it to a null distribution consisting of permuted scores resulting from random substitution of test parameters (e.g. a random selection out of all genes the same size as the cholinergic test set), the p-value being the fraction of the null distribution at least as extreme as the real score.

### Gene Ontology Analyses

We performed GO analyses on differentially expressed (DE) long RNA transcripts based on their DE p-value. GO analyses were performed using R/topGO as recommended by the authors, using the weighted method (8). Transcripts were ranked by p-value, and all DE transcripts (adjusted p-value  $< 0.05$ ) with absolute log<sub>2</sub> fold changes  $> 1.4$  were tested against the background of the topmost two thousand transcripts. While GO enrichment analysis can be informative, interpretation and visualization of its results is not standardized and is often limited to presentation of top *X* terms by p-value. R/gsoap (9) is an analysis tool proposed to aid in interpretation of GO enrichment results via t-SNE display of similarity of terms based on the amount of shared significant genes. GO enrichment results were processed to fulfil gsoap input criteria and visualized using R/ggplot2 (10).

### Pathways targeted by perturbed miRs

We determined target sets of positively and negatively DE miRs (separately) via *miRNeo* query with a threshold score of at least 6. The gene targets were ranked by the amount of miRs targeting each gene, yielding a range of 1-44 (mean 4.7  $\pm$  SD 4.7) for positively regulated miRs, and a range of 1-155 (mean 13.5  $\pm$  SD 15.6) for negatively regulated miRs, both resembling power law distributions. To account for possible biases in the underlying targeting dataset, targeting and scoring were then permuted for both sets with the same query and ranking, but randomized input miRs were selected from all mature miRs in the same length as the original DE set, for 10,000 times. Upon calculation of permutation p-values, we dismissed genes that were not targeted by the set of DE miRs significantly more than by the random permutation sets ( $p < 0.05$ ). The larger negative-DE set in this analysis yielded a large number of highly enriched genes, such that a distinction by adjusted p-value was not possible in the top 2000 targeted genes. Thus, we repeated the analysis for negatively regulated miRs using a log<sub>2</sub>FoldChange threshold of -2, which reduced the amount of miRs to 82, and the range of miRs targeting each gene to 1-52, mean 5.8  $\pm$  SD 6.1. This set was subjected to the same permutation approach and was used instead of the non-limited set in the p-value-based approach below.

The gene lists so derived were used in a GO analysis similar to the one described above, based on the following scorings: for positively regulated miRs, GO enrichment was based on 1) the significantly targeted genes ( $p < 0.05$ ) as a test set, and the (non-enriched,  $p > 0.05$ ) genes as background; and 2), to identify the most-targeted genes, the top 200 genes (sorted by amount of distinct miRs targeting each gene (also  $p < 0.05$ )) served as a test set, with all other genes (starting from 201) as the background. For negatively regulated miRs, target genes were analyzed similarly, but the non-threshold significantly targeted genes were replaced by the -2 log<sub>2</sub>FoldChange threshold set in approach 1). The GO terms yielded by these four analyses were visualized and clustered using the R/gsoap-approach described above.

The resulting 13 clusters were manually annotated and organized on a canvas to better understand the relationships between the targeted gene sets of positively and negatively regulated miRs ([Figure S5](#)).

Few terms fell outside the area of these manually adjoined clusters due to little similarity with the clustered terms; these were disregarded in the further analyses (but are available in [Data File S6](#)). To discern the most relevant genes and seek putative hub genes in the stroke response, the clusters identified in the gsoap visualization were imported back into the R environment. Detection of significantly enriched genes in each cluster involved hypergeometric enrichment of each gene in each cluster versus all other clusters (background) via Fisher's exact test. The resultant p-values were corrected for multiple testing using the Benjamini-Hochberg method, and genes with an adjusted p-value < 0.05 were considered significantly enriched in the respective cluster ([Data File S6](#)), with a range of enriched genes per cluster from 8 to 84. The final 13 clusters were ranked by the total amount of enriched genes per cluster, and cross-checked for functional implications of enriched genes in each cluster using DAVID 6.8 (11).

#### **PCR quantification of inflammatory markers after LPS stimulation and Zbp1 quantification.**

**LPS stimulation:** 18h after LPS stimulation, cells were collected in Tri-Reagent (Sigma Aldrich, St. Louis, USA) and total RNA, including small RNAs, isolated using miRNeasy (Qiagen, Hilden, Germany). cDNA was synthesized from 100ng RNA using qScript™ cDNA Synthesis Kit (Quanta Biosciences, Beverly MA, USA). Expression of Cd14, Stat1, Tnfa and Il10 were assessed using PerfeCTa® SYBR® Green FastMix® (Quanta Biosciences, Beverly MA, USA) and normalized using Peptidylprolyl isomerase A (Ppia) and 18S ribosomal RNA genes as house-keeping.

**ssRNA tRF-22-WE8SPOX52 mimics experiments:** 24h after transfection of the mimics, cells were collected in TRI-Reagent (Sigma Aldrich, St. Louis, USA) and total RNA, including small RNAs, isolated using miRNeasy (Qiagen, Hilden, Germany). cDNA was synthesized from 100ng RNA using qScript™ cDNA Synthesis Kit (Quanta Biosciences, Beverly MA, USA), and expression of Zbp1 was assessed using PerfeCTa® SYBR® Green FastMix® (Quanta Biosciences, Beverly MA, USA) and normalized using Glyceraldehyde 3-phosphate dehydrogenase (Gapdh) as house-keeping. Primer sequences were obtained from the Primer Bank (12) and were as follows:

Cd14: **FORWARD** AGCACACTCGCTCAACTTTTC,  
**REVERSE** GCCCAATTCAGGATTGTCAGAC  
Stat1: **F** TCACAGTGGTTCGAGCTTCAG, **R** CGAGACATCATAGGCAGCGTG  
Tnfa: **F** CCTGTAGCCACGTCGCTAG, **R** GGGAGTAGACAAGGTACAACCC  
Il-10: **F** GCTCTTACTGACTGGCATGAG, **R** CGCAGCTCTAGGAGCATGTG  
Ppia: **F** GAGCTGTTTGCAGACAAAGTTC, **R** CCCTGGCACATGAATCCTGG  
18S rRNA: **F** CTCAACACGGGAAACCTCAC, **R** CGCTCCACCACTAAGAACG  
Gapdh: **F** ATCAAGAAGGTGGTGAA, **R** CTTACTCCTTGAGAGCCAT

#### **PCR quantification of tRFs**

First, we performed size selection of total RNA, to exclude molecules > 25 nt in case of human samples and > 50 nt in case of cell culture experiments with RAW 264.7 cells. 1 µg of RNA was loaded into 15% TBE-Urea-Polyacrylamide gel (Biorad, Hercules, USA) after mixing 1:1 with Gel Loading Buffer II (Thermo Fisher, Waltham, USA) and run at 200V for 40-50 minutes. When testing human CD14+ monocytes, 600 ng of RNA were loaded into the gel; in case of low total RNA concentrations (with minimum 21 ng/µl), we used the maximum accommodable volume of 20 µl. Gels were stained with SYBR Gold (Thermo Fisher, Waltham, USA) and visualized on a UV table to cut out the desired section. As size markers, miR marker and Low Range ssRNA ladder (both from New England Biolabs, Ipswich, USA) were used. Excised gel fragments were incubated in 810µl 3M NaCl over-night at 4°C on a rotation stand. The supernatant was then transferred into a new Eppendorf and 1 volume of iso-propanol was added for 24h at -20°C. Then, RNA was precipitated.

RNA concentrations were measured using Bioanalyzer (Agilent, Santa Clara, USA) and cDNA was prepared from 500 pg (with exception of control samples 16 and 18 yielding low concentrations after size selection – here 250pg were used) using qScript™ microRNA cDNA Synthesis Kit (Quanta Biosciences, Beverly MA, USA) and diluted to 200 µl total. tRFs were quantified using quantitative reverse transcription PCR (RT-qPCR) with PerfeCTa® SYBR® Green FastMix®, Low ROX™ (Quanta Biosciences, Beverly MA, USA) and normalized to hsa-miR-30d-5p, hsa-let-7d-5p, hsa-miR-106b-3p and hsa-miR-3615 (human stroke patients) or mmu-miR-30d-5p, mmu-let-7d-5p for experiments with RAW 264.7 cells. In experiments with ssRNA tRF-22-WE8SPOX52 mimics, tRF-22-WE8SPOX52 levels were assessed without size-selection (measuring levels of the tRF and its parental tRNA molecule) and normalized to Snord47.

Primer sequences are listed below:

hsa/mmu-miR-30d-5p: TGTAACATCCCCGACTGGAAG

hsa/mmu-let-7d-5p: AGAGGTAGTAGGTTGCATAGTT

hsa-miR-106b-3p: CCGCACTGTGGGTACTTGCTGC

hsa-miR-3615: TCTCTCGGCTCCTCGCGGCTC

tRF-22-WEKSPM852: TCGATCCCCGGCATCTCCACCA

tRF-22-WE8SPOX52 (and tRF-21-WE8SPOX5D): TCGATTCCCGGCCAATGCACC

tRF-18-8R6Q46D2: TCCCCGGCATCTCCACCA


tRF-22-8EKSP1852: TCAATCCCCGGCACCTCCACCA

tRF-18-8R6546D2: TCCCCGGCACCTCCACCA

tRF-18-HR0VX6D2: ATCCCACCGCTGCCACCA

Snord47 (Quanta Biosciences, Beverly MA, USA):


GTGATGATTCTGCCAAATGATACAAAGTGATATCACCTTTAAACCGTTCCATTTTATTTCTGAGG



**Figure S1**

**Analysis of types of DE tRFs indicates non-random cleavage of tRNA molecules.**

Most DE tRFs were derived from tRNA-Ala (36) and 3'tRFs were the most common type in the whole DE dataset.




**Figure S2**


**Cholinergic-associated small RNA empirical cumulative distribution function (ECDF) curves.**

Cholinergic association was tested using *miRNeo* targeting data of miRs and tRFs.

To assess the best-suited threshold for defining cholinergic association, ECDFs were calculated for the number of cholinergic-associated (CA) genes targeted by each unique small RNA. A) Cumulative frequency of the number of CA genes targeted by tRFs. Threshold of 80% (red line) is passed at five CA genes targeted. B) Cumulative frequency of the number of CA genes targeted by miRs. Threshold of 80% (red line) is passed at four CA genes targeted.



**Figure S3**  
**tRF profiles of blood compartments distinguish leukocyte subsets, excluding neutrophils, from erythrocytes and non-cellular compartments.** t-SNE of specific blood compartments based on tRF expression, WB – whole blood, RBC – erythrocytes.



**Figure S4**  
**Most of top 20 stroke DE tRFs are present in immune cell compartments.** Heatmap showing the presence/absence of the 20 most highly-perturbed tRFs in defined blood compartments.





Figure 2: KEGG pathway map of the differentially expressed genes. The map shows various metabolic and cellular pathways. Key pathways include: G0050806 regulation of gene silencing (red circles), G0050847 regulation of posttranscriptional gene silencing (red circles), G0050848 production of riboflavin and gene silencing by miRNA (red circles), G0050849 negative regulation of cellular amino metabolic process (red circles), G0050851 protein synthesis (red circles), G0050852 cellular amino metabolic process, transcriptional down-regulation (red circles), G0050857 modified cellular metabolic process, transcriptional down-regulation (red circles), G0051014 protein synthesis of mRNA catalytic process (red circles), G0051126 protein histone methylation (green circles), G00508111 methanol+7-methylated signaling pathway (green circles), G00508182 cDNA helix-turn-helix assembly (green circles), G00504514 cDNA regulation of gene expression (green circles), G00503251 cDNA nuclear assembly (green circles), G00504512 regulation of negative protein differentiation (green circles), G00504513 negative protein differentiation (green circles), G0051010 gene silencing by miRNA (green circles), and G00510586 amino metabolic process (green circles).

Figure 2. Enrichment of biological processes in the heart muscle. The chart displays various biological processes and their corresponding gene counts (represented by bubble size) and p-values (represented by bubble color). The processes are categorized into two main groups: cardiac muscle hypertrophy and cardiac muscle proliferation/differentiation.

**Cardiac Muscle Hypertrophy (Left Side):**

- GO:0005885 negative regulation of cytoskeletal cell organization
- GO:0024112 glial morphogenesis
- GO:0043033 heart hypertrophy
- GO:0024490 regulation of transporter activity
- GO:0021438 regulation of transporter activity
- GO:0000765 muscle contraction
- GO:0051038 action potential
- GO:0071824 transmission of nerve impulse
- GO:0010613 positive regulation of cardiac muscle hypertrophy
- GO:0010611 positive regulation of cardiac muscle hypertrophy
- GO:0010612 positive regulation of cardiac muscle hypertrophy
- GO:0048870 homotetramerization of number of cells within a tissue
- GO:0001030 regulation of BDNF signaling pathway
- GO:0032079 negative regulation of coagulation
- GO:0000030 negative regulation of canonical Wnt signaling pathway

**Cardiac Muscle Proliferation and Differentiation (Right Side):**

- GO:0000108 cardiac muscle cell proliferation
- GO:0000017 cardiac muscle tissue growth
- GO:0000732 regulation of cardiac muscle cell differentiation
- GO:0000032 cardiac muscle cell development
- GO:0001148 positive regulation of muscle cell differentiation
- GO:0048846 anatomical structure formation involved in morphogenesis
- GO:0001033 regulation of cell adhesion
- GO:0004870 regulation of smooth muscle cell development
- GO:0004870 endothelial smooth muscle morphogenesis
- GO:0000062 endothelial differentiation
- GO:0000034 positive regulation of cell proliferation
- GO:0004036 positive regulation of cell differentiation
- GO:0000037 transcription initiation from RNA polymerase II promoter
- GO:0000031 positive regulation of cell differentiation
- GO:0000034 skeletal muscle cell differentiation
- GO:0004040 myofibrillar differentiation
- GO:0004040 myofibrillar contractile activity

Figure 2 displays a bubble chart illustrating the top 20 KEGG pathways for the 1000 most differentially expressed genes. The size of each bubble represents the number of genes in that pathway, and the color intensity represents the adjusted p-value. The pathways are labeled with their IDs and names. The top pathways include:

- GO:000122: negative regulation of transcription by RNA polymerase II
- GO:000141: regulation of RNA biosynthetic process
- GO:000143: alpha-beta T cell lineage commitment
- GO:004166: CD4-positive or CD8-positive alpha beta T cell lineage commitment
- GO:007258: T-helper 17 type immune response
- GO:000181: B cell receptor signaling pathway
- GO:000188: B cell proliferation
- GO:003320: interleukin-17 production
- GO:003343: regulation of interleukin-10 production
- GO:004046: regulation of activated T cell proliferation
- GO:003990: positive regulation of B cell proliferation
- GO:007162: B cell homeostasis
- GO:004269: T-bet-high differentiation
- GO:000115: negative regulation of CD4-positive, alpha beta T cell activation
- GO:000182: positive regulation of NLRP1 inflammasome signaling
- GO:001163: cytokine/cytokine receptor-mediated signaling pathway
- GO:000181: B cell receptor signaling pathway
- GO:000149: positive regulation of defense response
- GO:000103: positive regulation of response to viral stimulus
- GO:000181: B cell receptor signaling pathway

[illegible]

Figure 2: A network diagram showing the enrichment of biological processes. The diagram consists of two main columns of nodes, with lines connecting related processes. The nodes are represented by green circles of varying sizes, with larger nodes indicating higher enrichment. The left column contains nodes for humoral immune response, cytokine production, defense response to fungus, positive regulation of cytokine production, positive regulation of mast cell degranulation, positive regulation of mast cell mediator release, and positive regulation of mast cell histamine release. The right column contains nodes for positive regulation of leukocyte chemotaxis, positive regulation of response to cytokine stimulus, positive regulation of interleukin-6 production, positive regulation of cytokine production involved in immune response, response to prostaglandins, interferon-1 secretion, positive regulation of mast cell mediator production, serotonic metabolic process, anabolic metabolic process, and unsaturated fatty acid biosynthetic process. The central column contains nodes for cytokine production, positive regulation of cytokine production, positive regulation of mast cell degranulation, positive regulation of mast cell mediator release, positive regulation of mast cell histamine release, and positive regulation of mast cell mediator production.

GO:0005959 humoral immune response

GO:0005944 antigenic humoral immune response

GO:0005945 cytokine production

GO:0005946 defense response to fungus

GO:0005952 positive regulation of cytokine production

GO:0005953 positive regulation of mast cell degranulation

GO:0005954 positive regulation of mast cell mediator release

GO:0005955 positive regulation of mast cell histamine release

GO:0005956 positive regulation of leukocyte chemotaxis

GO:0005957 positive regulation of response to cytokine stimulus

GO:0005958 positive regulation of interleukin-6 production

GO:0005959 positive regulation of cytokine production involved in immune response

GO:0005960 response to prostaglandins

GO:0005961 interferon-1 secretion

GO:0005962 positive regulation of mast cell mediator production

GO:0005963 serotonic metabolic process

GO:0005964 anabolic metabolic process

GO:0005965 unsaturated fatty acid biosynthetic process

GO:0005966 cytokine production

GO:0005967 positive regulation of cytokine production

GO:0005968 positive regulation of mast cell degranulation

GO:0005969 positive regulation of mast cell mediator release

GO:0005970 positive regulation of mast cell histamine release

GO:0005971 positive regulation of mast cell mediator production

GO:0042428 positive regulation of potassium ion transport  
GO:005044 cell communication by electrical coupling  
GO:0010155 positive regulation of cell-cell contact  
GO:0007254 positive regulation of cytokinesis  
GO:0007079 regulation of calcium ion transport  
GO:0002114 regulation of gonadotropin-releasing hormone release  
GO:0007088 calcium ion transmembrane transport  
GO:0007277 cellular response to calcium ion  
GO:0019327 anion transport  
GO:0003198 regulation of muscle contraction  
GO:0003016 regulation of muscle structure  
GO:1903232 negative regulation of blood circulation  
GO:0008901 regulation of cardiac muscle cell action  
GO:0001190 regulation of sensory perception of pain  
GO:0008277 regulation of G-protein-coupled receptor

[illegible]

GO:0012016: regulation of cold-induced thermogenesis

GO:0010675: regulation of cellular carbohydrate metabolic process

GO:0006004: acetyl-CoA metabolic process

GO:0016125: steroid metabolic process


GO:0000181: regulation of cholesterol metabolism

GO:1902930: regulation of alcohol biosynthesis


- GO:1905268: negative regulation of chromatin organization
- GO:0031935: regulation of chromatin silencing
- GO:0002969: negative regulation of gene silencing
- GO:0045815: positive regulation of gene expression

**Figure S5 (on previous page)**


**Ontological enrichment and clustering of gene target sets of DE miRs show distinct perturbed pathways.** Gene target sets of positively and negatively perturbed miRs were subjected to gene ontology analysis separately, based on two scoring systems: “pval,” based on enrichment p-value in targeting permutation, and “top200”, based on the top 200 genes with highest amounts of miRs targeting each gene. Resulting GO terms were visualized using R/gsoap and clustered based on their shared genes (upper left). Circle sizes represent the number of genes in each term, their color depth denotes p-value (all  $p < 0.05$ ). The single clusters were manually screened and annotated regarding their functions (right side).



**Figure S6**  
**Upregulated inflammatory signaling molecules and cytokines in LPS-stimulated murine RAW 264.7 cells.** A) Levels of cluster of differentiation 14 (Cd14), signal transducer and activator of transcription 1 (Stat1), tumor necrosis factor alpha (Tnfa) and interleukin 10 (Il-10) were measured with RT-qPCR using normalized expression (Ppia and 18SrRNA served as house-keeping), relative to the nonstimulated control group (line at mean normalized expression for the control group = 1), Each dot represents 2-4 technical replicates, ANOVA with Tukey post-hoc, \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ , bar graphs  $\pm$  SD(lg).



**Figure S7**  
**tRF-22-WE8SPOX52 expression in the ssRNA mimics transfection experiments.** Shown is normalized expression of tRF-22-WE8SPOX52 and parental tRNA molecule (measurement without size selection) by RT-qPCR using Snord47 as house-keeping gene. A) Experiment 1 - samples subjected to long RNA sequencing. B) Experiment 2 - samples used for RT-qPCR measurements of Zbp1 expression. Each dot represents one technical replicate in the cell culture experiment. \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ , one-way ANOVA, bar graphs  $\pm$  SD(Ig).



**Figure S8**  
**LPS stimulation of human CD14<sup>+</sup> cells yields transient nicotine-affected tRF changes.** The top 6 stroke-perturbed tRFs were quantified in human CD14<sup>+</sup> cells following LPS stimulation with and without addition of nicotine; controls were nonstimulated cells and cells with nicotine alone (for setup, see Figure 6G in the main manuscript). A) Cells collected 6h after LPS stimulation showed significantly elevated tRF-18-8R6546D2 under LPS + nicotine exposure alone. B) At 18h after LPS stimulation, none of the

top 6 stroke-perturbed tRFs showed significant changes, including LPS +nicotine challenged cells which showed upregulation at the 12h time point (see Figure 6H in the main manuscript). LPS-stimulated cells still showed the highest expression of tRFs, albeit not significant when compared to other groups. #  $p < 0.05$  when compared to nicotine-treated cells. Each dot represents one donor, one-way ANOVA with Tukey post-hoc; bar graphs  $\pm$  SD(lg). C) LPS-stimulation led to significantly elevated  $\text{TNF}\alpha$  levels in the supernatant of CD14<sup>+</sup> cells (measured by ELISA). \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ , two-way ANOVA on the influence of group and time variable on the  $\text{TNF}\alpha$  levels.  $F(3, 60) = 23.53$ ,  $p < 0.0001$  for the main effect “group” (nonstimulated, LPS, LPS + nicotine and nicotine),  $F(2,60) = 7.56$   $p = 0.0012$  for the main effect “time”,  $F(6, 60) p=0.02$  for the interaction; with Dunnett’s post-hoc performing comparisons LPS group vs. others; bar graph  $\pm$  SD.

5' AUCCCACCGCUGCCACCA 3'	trF-18-HR0VX6D2
5' AUCCCACCAACUGCCACCAU 3'	hsa-miR-1260b
5' AUCCCACCUUGCCACCA 3'	hsa-miR-1260a

**Figure S9**

**Sequence of tRF-18-HR0VX6D2 shows high similarities to two known miRs (13)**

hsa-miR-1260b differs from tRF-18-HR0VX6D2 by one nucleotide at position 9 and an additional nucleotide at the 3'-end, has-miR-1260a differs from tRF-18-HR0VX6D2 only at position 9.

GO.ID	Term	Annotated	Significant	Expected	Rank in classic	classic	weight
GO:0001819	positive regulation of cytokine producti...	66	14	4.38	42	6E-05	0.00017
GO:0032479	regulation of type I interferon producti...	29	8	1.93	52	0.00039	0.00039
GO:0001818	negative regulation of cytokine producti...	51	11	3.39	51	0.00034	0.00057
GO:0009617	response to bacterium	95	18	6.31	35	2.5E-05	0.00059
GO:0045087	innate immune response	151	38	10.03	1	9.1E-15	0.00197
GO:0098586	cellular response to virus	15	5	1	65	0.00208	0.00208
GO:0046683	response to organophosphorus	22	6	1.46	68	0.00233	0.00233
GO:0002753	cytoplasmic pattern recognition receptor...	10	4	0.66	70	0.00284	0.00284
GO:0048661	positive regulation of smooth muscle cel...	16	5	1.06	72	0.00286	0.00286
GO:0060760	positive regulation of response to cytok...	16	5	1.06	73	0.00286	0.00286
GO:0014074	response to purine-containing compound	23	6	1.53	75	0.00299	0.00299
GO:0032649	regulation of interferon-gamma productio...	17	5	1.13	80	0.00384	0.00384
GO:0016525	negative regulation of angiogenesis	12	4	0.8	88	0.00603	0.00603
GO:0034446	substrate adhesion-dependent cell spread...	13	4	0.86	93	0.00827	0.00827
GO:0032496	response to lipopolysaccharide	46	8	3.06	96	0.00917	0.00917
GO:0009063	cellular amino acid catabolic process	14	4	0.93	100	0.01099	0.01099
GO:0031349	positive regulation of defense response	58	11	3.85	61	0.00109	0.01236
GO:0002576	platelet degranulation	22	5	1.46	102	0.01252	0.01252
GO:0010469	regulation of signaling receptor activit...	49	8	3.26	103	0.01340	0.01340
GO:0070887	cellular response to chemical stimulus	404	54	26.84	19	6.2E-09	0.01563
GO:0030168	platelet activation	32	6	2.13	111	0.01641	0.01641
GO:0034109	homotypic cell-cell adhesion	16	4	1.06	112	0.01802	0.01802
GO:0050731	positive regulation of peptidyl-tyrosine...	25	5	1.66	117	0.02152	0.02152
GO:0048469	cell maturation	17	4	1.13	118	0.02238	0.02238
GO:0097696	STAT cascade	17	4	1.13	119	0.02238	0.02356
GO:0043330	response to exogenous dsRNA	10	3	0.66	123	0.02429	0.02429
GO:0071695	anatomical structure maturation	18	4	1.2	127	0.02734	0.02734
GO:0050680	negative regulation of epithelial cell p...	19	4	1.26	139	0.03290	0.03290
GO:0007267	cell-cell signaling	146	11	9.7	649	0.37575	0.03503
GO:0001936	regulation of endothelial cell prolifera...	20	4	1.33	145	0.03907	0.03907
GO:0006906	vesicle fusion	20	4	1.33	146	0.03907	0.03907
GO:0007160	cell-matrix adhesion	20	4	1.33	147	0.03907	0.03907
GO:0030856	regulation of epithelial cell differenti...	12	3	0.8	151	0.04041	0.04041
GO:0034113	heterotypic cell-cell adhesion	12	3	0.8	152	0.04041	0.04041
GO:0042130	negative regulation of T cell proliferat...	12	3	0.8	153	0.04041	0.04041
GO:0051668	localization within membrane	12	3	0.8	154	0.04041	0.04041

**Table S1**  
**Post-stroke DE genes are enriched in circulation- and immunity- related pathways.**  
Full list of GO terms used for generation of tSNE in [Figure 4](#) (main manuscript).



## References:

1. M. I. Love, W. Huber, S. Anders, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15** (2014).
2. A. Zhu, J. G. Ibrahim, M. I. Love, Heavy-tailed prior distributions for sequence count data: removing the noise and preserving large differences. *Bioinformatics* **35**, 2084–2092 (2019).
3. S. Lobentanzer, G. Hanin, J. Klein, H. Soreq, Integrative Transcriptomics Reveals Sexually Dimorphic Control of the Cholinergic/Neurokinin Interface in Schizophrenia and Bipolar Disorder. *Cell Rep.* **29**, 764–777.e5 (2019).
4. V. Agarwal, G. W. Bell, J. W. Nam, D. P. Bartel, Predicting effective microRNA target sites in mammalian mRNAs. *Elife* **4** (2015).
5. R. C. Friedman, K. K. H. Farh, C. B. Burge, D. P. Bartel, Most mammalian mRNAs are conserved targets of microRNAs. *Genome Res.* **19**, 92–105 (2009).
6. H. Soreq, Checks and balances on cholinergic signaling in brain and body function. *Trends Neurosci* **38**, 448–458 (2015).
7. D. Marbach, *et al.*, Tissue-specific regulatory circuits reveal variable modular perturbations across complex diseases. *Nat. Methods* **13**, 366–370 (2016).
8. A. Alexa, J. Rahnenfuhrer, T. Lengauer, Improved scoring of functional groups from gene expression data by decorrelating GO graph structure. *Bioinformatics* **22**, 1600–1607 (2006).
9. T. Tokar, C. Pastrello, I. Jurisica, GSOAP: a tool for visualization of gene set over-representation analysis. *Bioinformatics* (2020) <https://doi.org/10.1093/bioinformatics/btaa001>.
10. H. Wickham, *ggplot2: Elegant Graphics for Data Analysis* (Springer-Verlag, 2016).
11. D. W. Huang, B. T. Sherman, R. A. Lempicki, Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat. Protoc.* **4**, 44–57 (2009).
12. X. Wang, A. Spandidos, H. Wang, B. Seed, PrimerBank: A PCR primer database for quantitative gene expression analysis, 2012 update. *Nucleic Acids Res.* **40**, D1144–D1149 (2012).
13. N. C. T. Schopman, S. Heynen, J. Haasnoot, B. Berkhout, A miRNA-tRNA mix-up: tRNA origin of proposed miRNA. *RNA Biol.* **7**, 573–576 (2010).